Please login to the form below

Not currently logged in
Email:
Password:

Roche and Illumina partner on genomics for cancer diagnostics

Will leverage genomics system to match optimal cancer treatment

Roche building logo

Roche and Illumina have announced a 15-year alliance for genomics testing, aimed at transforming cancer diagnostics. 

The non-exclusive partnership will broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology. The financial terms of the deal were not disclosed.

The companies are aiming to define a patient’s unique cancer using the genomics systems and use this resulting genomic pattern to match optimal treatment, including Roche's targeted cancer therapy portfolio.

Under the terms of the agreement, Illumina will grant Roche rights to develop and distribute in vitro diagnostic tests on Illumina’s NextSeq 550Dx system, as well as on its future portfolio of diagnostic sequencing systems.

Roche will collaborate with Illumina to complement its comprehensive pan-cancer blood assay TruSight Oncology 500 (TSO 500) with new companion diagnostic (CDx) claims.

TSO 500 uses DNA and RNA biomarkers from tumour samples to identify genetic variants linked to disease progression.

“This collaboration is uniquely positioned to improve medical value and clinical decision making globally by combining the unique capabilities of the Roche Group including Foundation Medicine with Illumina and will provide more patients with access to NGS to characterise their disease and identify the right treatment for them,” said Thomas Schinecker, CEO of Roche Diagnostics.

“This builds upon our strategy of accelerating clinical research, streamlining workflows and expanding assay menus to broaden access to genomic data and lower barriers to routine use,” he added.

Roche plans to develop, manufacture and commercialise its Avenio IVD test kits for both tissue and blood use on Illumina’s Next Seq 550Dx system, while Illumina continues to sell the system and its core sequencing consumables.

“This partnership complements and strengthens our strategy to establish TSO 500 as a comprehensive NGS panel for cancer therapies by expanding the supported set of CDx claims on this universal panel,” said Francis deSouza, CEO of Illumina.

“Building on the momentum of other recently established diagnostic and pharmaceutical partnerships, together we aim to advance critical access to NGS testing to improve patient outcomes,” he added

Article by
Lucy Parsons

15th January 2020

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics